Amiodarone is effective for various arrhythmias but its use is restricted to serious ventricular tachyarrhythmias due to numerous serious side effects.
Cautions broad arrhythmia use in practice; leaves open development of safer agents with wider indications.
IN December 1985, amiodarone (Cordarone) was approved in the United States for treatment of life-threatening ventricular tachyarrhythmias. It is effective not only in these arrhythmias but also in less severe ventricular arrhythmias and many supraventricular arrhythmias, including atrial fibrillation and reentrant tachyarrhythmias involving accessory pathways. Its approval restricts its use to serious ventricular tachyarrhythmias, because amiodarone produces numerous side effects, some of which are serious.PharmacokineticsAmiodarone is absorbed slowly (the peak level is reached four to five hours after an oral dose), with low bioavailability that varies markedly among individuals.1 , 2 This low availability, and perhaps the variability, are thought . . .
No takes yet. Share an insight, caveat, or question.
Oates et al. (1987) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: